Related Experiment Video

Updated: Aug 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Double-blind study on the activity of plafibride in the treatment of type IV hyperlipoproteinemia

I J Ferreira, A del Rio, N González-Viejo

    Arzneimittel-Forschung
    |January 1, 1981
    PubMed

    Insights

    Plafibride (ITA 104) effectively reduced triglycerides in type IV hyperlipoproteinemia patients, showing promise for managing associated thromboembolic risks. The drug demonstrated good tolerance and improved platelet function.

    Area of Science:

    • Pharmacology
    • Cardiovascular Medicine
    • Lipid Metabolism

    Background:

    • Type IV hyperlipoproteinemia is characterized by elevated triglycerides and increased risk of atherosclerotic and thromboembolic diseases.
    • Current treatments for hyperlipoproteinemia often have limitations or side effects.
    • There is a need for effective therapeutic agents to manage lipid profiles and reduce cardiovascular risk.

    Purpose of the Study:

    • To evaluate the efficacy and safety of plafibride (ITA 104) in patients with type IV hyperlipoproteinemia.
    • To assess the drug's impact on lipid levels, lipoprotein fractions, and platelet function.
    • To determine the overall tolerability and potential adverse effects of plafibride.

    Main Methods:

    • A double-blind, four-month study involving 30 patients diagnosed with type IV hyperlipoproteinemia.
    • Patients were treated with either plafibride (ITA 104) or a placebo.
    • Measurements included blood lipid levels (triglycerides, cholesterol), lipoproteinogram analysis, and platelet aggregation studies.

    Main Results:

    • Significant reductions in blood triglycerides were observed in the plafibride group, trending towards normal levels.
    • Cholesterol reduction was inconsistent and not statistically significant.
    • Plafibride demonstrated a notable decrease in platelet aggregation, particularly with ADP and adrenaline induction, suggesting reduced thrombotic risk.
    • The drug was generally well-tolerated, with minor, transient side effects reported in a few patients. No significant renal, hepatic, or hematological abnormalities were detected.

    Conclusions:

    • Plafibride (ITA 104) is a potentially valuable therapeutic option for type IV hyperlipoproteinemia, especially in patients with suspected increased thromboembolic risk.
    • The drug's ability to reduce triglycerides and inhibit platelet aggregation warrants further investigation for cardiovascular disease prevention.
    • Plafibride exhibits a favorable safety profile, making it a promising candidate for long-term management of hyperlipoproteinemia.

    More Related Videos

    Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model08:20

    Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model

    Published on: December 2, 2022

    Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

    Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

    Published on: April 7, 2023

    Related Concept Videos

    Blind Procedures02:07

    Blind Procedures

    Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
    Blinding01:11

    Blinding

    Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Peripheral Artery Disease III: Interprofessional Care01:27

    Peripheral Artery Disease III: Interprofessional Care

    Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...